The Key to Success is in Our People

Board of Directors

Tadataka-Yamada

Tadataka Yamada, MD, KBE

Chairman of the Board

Dr. Tadataka (Tachi) Yamada is currently a Venture Partner with Frazier Healthcare Partners and Chairman of the Board of Directors at Prometheus Biosciences. Prior to joining Frazier, he was Executive Vice-President, Chief Medical and Scientific Officer and a Board Member of Takeda Pharmaceuticals. He was formerly President of the Bill & Melinda Gates Foundation Global Health Program. In this capacity he oversaw grants totaling over $9 billion in programs directed at applying technologies to address major health challenges of the developing world including TB, HIV, malaria and other infectious diseases, malnutrition and maternal and child health. He was previously Chairman of R&D at GlaxoSmithKline and before that Chairman of the Department of Internal Medicine and Physician-in-Chief at the University of Michigan Medical Center.

Close
Mark-McKenna

Mark McKenna

President & CEO, Board Member

Mr. McKenna serves as President, CEO and member of the board of Prometheus Biosciences. Prior to joining Prometheus Biosciences, Mr. McKenna was President & CEO of Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies.  He joined Salix in March 2016 as the Senior Vice President and General Manager, responsible for the company’s gastrointestinal franchise. During his tenure, Mr. McKenna successfully led the company through a series of key strategic acquisitions, the launch of a number of new products, and delivered strong operating performance, with revenue increasing from $1.2B to $2B. Prior to joining Salix, Mr. McKenna spent more than a decade with Bausch + Lomb, most recently as Senior Vice President/General Manager of its U.S. Vision Care business.  Prior to Bausch + Lomb, Mark held several roles of increasing responsibility at Johnson & Johnson.  Mark holds a B.S. in Marketing from Arizona State University, an MBA from Azusa Pacific University and is a Fellow with the University of Pennsylvania, Wharton School of Business. 

Close
Greg-Behar

Greg Behar

Board Member

Greg started his career in 1993 in an Engineering company in Switzerland and joined Nestlé in 1995 in Brazil and Switzerland before working at Novartis Pharma in Spain and at global headquarters in Switzerland. In 2010, he joined Boehringer Ingelheim where he was responsible for various regions and for the Cardiovascular and Metabolic franchise. In 2011, he was appointed President & CEO of Boehringer Ingelheim Pharmaceuticals, Inc. in the USA, responsible for sales of USD 5.5 billion and over 5,000 employees. On October 1st, 2014, Greg was appointed CEO for Nestlé Health Science SA, a wholly-owned subsidiary of Nestlé SA. He is also a Board member of Cerecin, Inc., Seres Therapeutics, Inc., Axcella Health Inc. and Aimmune Therapeutics, Inc. Mr. Behar obtained a Master of Science in Mechanical Engineering and Manufacturing from the EPFL, near Lausanne, coupled with an MBA from INSEAD in France.

Close
Scott-Glenn

Scott Glenn

Board Member

Mr. Glenn currently serves as the Managing Partner of Windamere Venture Partners, LLC and is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences. He has founded over twenty successful biotech companies and has over twenty-five years of experience as Chairman/CEO and founder of Quidel, Prometheus Labs, DexCom, Santarus, Kanisa, Exagen Diagnostics, Oncternal and Alastin Skincare. Mr. Glenn is also founder of SpineWave Zogenix, Cadence Pharmaceuticals, NovaCardia, SkinMedica, Conception Technologies and Somaxon. Mr. Glenn also held various management positions, including Division General Manager with Allergan, Inc.

Close
James-Laur

James Laur

Board Member

James Laur is vice president, Intellectual Property and heads up Cedars-Sinai Technology Ventures reporting to the health system’s chief financial officer. Mr. Laur’s primary responsibilities are focused on innovation, technology transfer and international business activities. He drives new business development and investment opportunities involving innovation and technology-related activities at Cedars-Sinai and its global partners. Laur serves as co-executive sponsor of the Cedars-Sinai Accelerator Program and also represents Cedars-Sinai on the board of directors of some of its spinoff companies and other investments. He holds dual bachelor’s degrees, with honors, from UCLA in political science and philosophy. He earned his doctorate of law degree, cum laude, from the Boston College Law School.

Close
Shlomo-Melmed

Shlomo Melmed, MB, ChB

Board Member

Dr. Melmed received his medical degree with distinction from the University of Cape Town, School of Medicine in 1970. At Cedars-Sinai since 1980, he is executive vice president for academic affairs, and dean of the medical faculty. He holds the Helene A. and Philip E. Hixon Distinguished Chair in Investigative Medicine and has been funded by NIH for translational and clinical discovery in pituitary medicine since 1980. Recipient of multiple awards from the Endocrine Society, UK Society of Endocrinology and American Association of Endocrinology, he edits the major endocrine textbooks used globally, and is a director of CA Institute of Regenerative Medicine and of CA Life Sciences Association. At Cedars-Sinai, Dr. Melmed has spearheaded major academic growth and development, recruiting talented nationally recognized faculty leadership, establishing new programs and maintaining standards of excellence for educational programs, all propelling Cedars-Sinai to top tier national ranking.

Close
William-Sandborn

William Sandborn, MD

Chairman of Scientific Advisory Board

Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became a tenured Professor of Medicine and Adjunct Professor of Surgery at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. He was previously a co-founder of Santarus working directly with Scott Glenn, Stephan Targan & Gerry Proehl. Dr. Sandborn has published over 720 peer reviewed articles and is a member of the editorial board for the New England Journal of Medicine.

Close
Mark-Stenhouse

Mark Stenhouse

Board Member

Mr. Stenhouse is President, of the Cologuard franchise at Exact Sciences where he leads the commercial functions including, sales, marketing, market access, commercial operations and medical affairs. Prior to joining Exact Sciences, Mr. Stenhouse was at Abbott Laboratories/AbbVie, where he led the sales and marketing teams for one of the most successful pharmaceutical products. During nearly 30 years at the company, his roles included Vice President, US Immunology, AbbVie, Vice President Gastroenterology, AbbVie, Sr. Director, Immunology, Abbott Laboratories, Marketing Director, Immunology, Abbott Laboratories, and Nationals Sales Director, Immunology, Abbott Laboratories.

Close
Douglas-Wall

Douglas Wall

Board Member

Douglas Wall is the Managing Member and Managing Director of Life Ventures which focuses on investing into lifesaving technology companies including Daylight Solutions, PureForge, Alastin Skincare and Precision IBD. Mr. Wall serves as Chairman of the Board for Tech M3, Inc. dba PureForge. He has a track record of investing and leading successful fund formation, including Mission Ventures and Shepherd Ventures, which have been successful venture capital funds based in San Diego. Mr. Wall has an accomplished career of providing strategic advisory services to privately owned and emerging companies and private equity funds. During his career, Mr. Wall co-founded several entrepreneurial ventures including PureForge, Genea Energy, Tech Coast Angels and RCG Management. Prior to starting his first entrepreneurial venture, RCG, which provided strategic services to over 3,000 emerging growth companies, Mr. Wall was a manager with Ernst & Young and a senior with Arthur Andersen.

Close
Shierley-Widjaja

Shierley Widjaja

Board Member

Ms. Shierley Widjaja is an Executive Director and Chief Investment Officer of SJE Investments, the family office of Mr. Franky Widjaja, the Chief Executive Officer of Golden Agri Resources. SJE invests in a broad range of asset classes including public equity, fixed income, private companies, and alternatives such as venture capital and hedge funds. Prior to starting SJE Investments, Ms. Widjaja was a Portfolio Manager at McKinley Capital Management, specializing in global growth equity strategies. She started her career as an Analyst at UBS Investment Bank in Hong Kong, specializing in Mergers and Acquisitions. Ms. Widjaja obtained her Master of Business Administration from the Wharton School, University of Pennsylvania with a Finance and Accounting concentration. Ms. Widjaja graduated from University of California Los Angeles, Summa Cum Laude, with a Bachelor of Science in Electrical Engineering.

Close

Scientific Advisory Board

William-Sandborn

William Sandborn, MD

Chairman of Scientific Advisory Board

Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became a tenured Professor of Medicine and Adjunct Professor of Surgery at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. He was previously a co-founder of Santarus working directly with Scott Glenn, Stephan Targan & Gerry Proehl. Dr. Sandborn has published over 720 peer reviewed articles and is a member of the editorial board for the New England Journal of Medicine.

Close

Donna Griebel, MD

Scientific Advisor

Donna Griebel, M.D. is former Director of the Division of Gastroenterology and Inborn Errors Products (DGIEP) in the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA). As acting Director, she regulated Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologics Licensing Applications (BLAs) for drugs and therapeutics biologics intended for the treatment and prevention of gastrointestinal, hepatic and nutritional disorders and inborn error of metabolism. In her prior position, Dr. Griebel was Deputy Director of the Division of Reproductive and Urologic products where she oversaw the safety and efficacy of drugs and therapeutic biologics aimed to improving reproductive and urologic health. She has extensive regulatory experience in drug development and served on CDER's Medical Policy Council (MPC) and the MPC's Subcommittee on Safety Outcome Trials.    

Close
Dermot-McGovern

Dermot McGovern, MD, PhD

Scientific Advisor

Dr. McGovern is a gastroenterologist and preeminent geneticist in the IBD field. Dr. McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford, England before moving to Cedars-Sinai. Dr. McGovern is the Director of Translational Medicine at Cedars, co-Director of the Cedars-Sinai IBD repository (MIRIAD) and IBD Database and was recently appointed the Director of Precision Health at Cedars-Sinai. Dr. McGovern serves on both the Steering Committee of the NIDDK IBD Genetics Consortium, and on the Management Committee of the International IBD Genetics Consortium. Dr. McGovern is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences and serves as the consulting geneticist and provides input on the patient selection criteria.

Close
Luisa-Salter

Luisa Salter-Cid, PhD

Scientific Advisor

Luisa Salter-Cid, Ph.D. currently serves as the Chief Scientific Officer of Gossamer Bio where she oversees a Research team focused on bringing Immunology-based innovative medicines up to IND filling. Prior to joining Gossamer, Dr. Salter-Cid spent 13 years at Bristol Myers Squibb where she held several positions including Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery. In this position, she oversaw several biology groups that focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. During her time at BMS, Dr. Salter-Cid led teams that advanced more than 20 compounds into clinical development. She was also Chair of the Immunoscience Target Science Team (TST) and a core member of several executive committees focused on strategy, development and external collaborations. Prior to joining BMS, she was a Senior Project Leader at La Jolla Pharmaceuticals where she led discovery projects. She also held positions at Genset Corp and Johnson & Johnson. 

Close
Bruce-Sands

Bruce E. Sands, MD

Scientific Advisor

Bruce E. Sands, M.D. is the head of the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai in New York, NY.  He also serves as the Dr. Burrill B. Crohn’s Professor and Chief of Gastroenterology at Mount Sinai. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital's Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School. He is a fellow of the American College of Gastroenterology and the American Gastroenterological Association and is reviewer for the New England Journal of Medicine. Dr. Sands received his medical degree at Boston University School of Medicine and completed a residency in internal medicine at the Hospital of the University of Pennsylvania.  He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.

Close
Stephan-Targan

Stephan Targan, MD

Scientific Advisor

Dr. Targan is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences and is currently the Director of the Inflammatory Bowel and Immunobiology Research Institute at Cedars-Sinai Medical Center. Dr. Targan began his career at UCLA School of Medicine in 1978 and then moved his laboratories and practice in 1992 to establish the IBD Center at Cedars-Sinai. Dr. Targan has focused on identifying drivers of IBD pathogenesis, which in the context of such a genetically heterogeneous disease, involves numerous biologic and molecular pathways and comprises complex relationships between the intestinal microenvironment and the immune response. With over four decades of experience in treating IBD patients and over 300 peer-reviewed articles, Dr. Targan is a recognized leader in inflammatory bowel diseases. He was previously a co-founder of Santarus and Prometheus Laboratories.

Close